Genome Editing-Enabled HTS Assays Expand Drug Target Pathways for Charcot–Marie–Tooth Disease

Copy number variation resulting in excess PMP22 protein causes the peripheral neuropathy Charcot–Marie–Tooth disease, type 1A. To broadly interrogate chemically sensitive transcriptional pathways controlling PMP22 protein levels, we used the targeting precision of TALEN-mediated genome editing to embed reporters within the genetic locus harboring the Peripheral Myelin Protein 22 (Pmp22) gene. Using a Schwann cell line with constitutively high endogenous levels of Pmp22, we obtained allelic insertion of secreted bioluminescent reporters with sufficient signal to enable a 1536-well assay. Our findings from the quantitative high-throughput screening (qHTS) of several thousand drugs and clinically investigated compounds using this assay design both overlapped and expanded results from a previous assay using a randomly inserted reporter gene controlled by a single regulatory element of the Pmp22 gene. A key difference was the identification of a kinase-controlled inhibitory pathway of Pmp22 transcription revealed by the activity of the Protein kinase C (PKC)-modulator bryostatin.

[1]  L. Gutmann,et al.  Update on Charcot-Marie-Tooth disease. , 2015, Current opinion in neurology.

[2]  Dana Carroll,et al.  Genome engineering with targetable nucleases. , 2014, Annual review of biochemistry.

[3]  R. Lewis,et al.  High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial. , 2013, JAMA neurology.

[4]  Dmitry Malkov,et al.  Tagging of Genomic STAT3 and STAT1 with Fluorescent Proteins and Insertion of a Luciferase Reporter in the Cyclin D1 Gene Provides a Modified A549 Cell Line to Screen for Selective STAT3 Inhibitors , 2013, PloS one.

[5]  A. Newton,et al.  Protein kinase C pharmacology: refining the toolbox. , 2013, The Biochemical journal.

[6]  D. Auld,et al.  Reporter enzyme inhibitor study to aid assembly of orthogonal reporter gene assays. , 2013, ACS chemical biology.

[7]  Brock F. Binkowski,et al.  Engineered Luciferase Reporter from a Deep Sea Shrimp Utilizing a Novel Imidazopyrazinone Substrate , 2012, ACS chemical biology.

[8]  James Inglese,et al.  Identification of drug modulators targeting gene-dosage disease CMT1A. , 2012, ACS chemical biology.

[9]  H.-L. Zhu,et al.  The chemistry and biology of the bryostatins: potential PKC inhibitors in clinical development. , 2012, Current medicinal chemistry.

[10]  H. Houlden,et al.  Charcot–Marie–Tooth disease: frequency of genetic subtypes and guidelines for genetic testing , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[11]  S. Keleş,et al.  Distal enhancers upstream of the Charcot-Marie-Tooth type 1A disease gene PMP22. , 2012, Human molecular genetics.

[12]  U. Suter,et al.  Molecular mechanisms regulating myelination in the peripheral nervous system , 2012, Trends in Neurosciences.

[13]  Ruili Huang,et al.  The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics , 2011, Science Translational Medicine.

[14]  R. Nagarajan,et al.  Regulation of the PMP22 Gene through an Intronic Enhancer , 2011, The Journal of Neuroscience.

[15]  M. Reilly,et al.  Charcot‐Marie‐Tooth disease , 2011, Journal of the peripheral nervous system : JPNS.

[16]  Elo Leung,et al.  A TALE nuclease architecture for efficient genome editing , 2011, Nature Biotechnology.

[17]  M. Shy,et al.  Update on Charcot-Marie-Tooth Disease , 2011, Current neurology and neuroscience reports.

[18]  M. Shy,et al.  Charcot‐marie‐tooth disease subtypes and genetic testing strategies , 2011, Annals of neurology.

[19]  J. Lupski,et al.  Mechanisms for nonrecurrent genomic rearrangements associated with CMT1A or HNPP: rare CNVs as a cause for missing heritability. , 2010, American journal of human genetics.

[20]  D. Auld,et al.  Illuminating insights into firefly luciferase and other bioluminescent reporters used in chemical biology. , 2010, Chemistry & biology.

[21]  L. Wrabetz,et al.  Signals to promote myelin formation and repair , 2010, Nature Reviews Neurology.

[22]  F. Ruissen,et al.  Copy number variation upstream of PMP22 in Charcot–Marie–Tooth disease , 2010, European Journal of Human Genetics.

[23]  L. Notterpek,et al.  Peripheral myelin protein 22 is regulated post‐transcriptionally by miRNA‐29a , 2009, Glia.

[24]  Peter G Schultz,et al.  Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4 , 2009, Proceedings of the National Academy of Sciences.

[25]  B. Tannous,et al.  Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo , 2009, Nature Protocols.

[26]  L. Notterpek,et al.  Identification of Dynamically Regulated MicroRNA and mRNA Networks in Developing Oligodendrocytes , 2008, The Journal of Neuroscience.

[27]  M. Mcdermott,et al.  Neuropathy progression in Charcot-Marie-Tooth disease type 1A , 2008, Neurology.

[28]  Adam Yasgar,et al.  Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[29]  K. Jooss,et al.  Stable antibody expression at therapeutic levels using the 2A peptide , 2005, Nature Biotechnology.

[30]  R. Weissleder,et al.  Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[31]  M. Fontès,et al.  Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease , 2004, Nature Medicine.

[32]  K. Nave,et al.  Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A) , 2003, Nature Medicine.

[33]  J. Perea,et al.  Comparison of a new pmp22 transgenic mouse line with other mouse models and human patients with CMT1A * , 2002, Journal of anatomy.

[34]  J. Perea,et al.  Induced myelination and demyelination in a conditional mouse model of Charcot-Marie-Tooth disease type 1A. , 2001, Human molecular genetics.

[35]  P. Patel,et al.  Glucocorticosteroids stimulate the activity of the promoters of peripheral myelin protein-22 and protein zero genes in Schwann cells , 2000, Brain Research.

[36]  G A Petsko,et al.  Chemistry and biology. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[37]  J. Chan,et al.  Glucocorticoids and progestins signal the initiation and enhance the rate of myelin formation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[38]  D. Figarella-Branger,et al.  Correlation between varying levels of PMP22 expression and the degree of demyelination and reduction in nerve conduction velocity in transgenic mice. , 1998, Human molecular genetics.

[39]  A. Aguzzi,et al.  Impaired Differentiation of Schwann Cells in Transgenic Mice with Increased PMP22 Gene Dosage , 1996, The Journal of Neuroscience.

[40]  D. Figarella-Branger,et al.  Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA. , 1996, Human molecular genetics.

[41]  K. Nave,et al.  A Transgenic Rat Model of Charcot-Marie-Tooth Disease , 1996, Neuron.

[42]  J. Small,et al.  Biochemical and Cellular Properties of Three Immortalized Schwann Cell Lines Expressing Different Levels of the Myelin‐Associated Glycoprotein , 1994, Journal of neurochemistry.

[43]  S. Schneider-Maunoury,et al.  Krox-20 controls myelination in the peripheral nervous system , 1994, Nature.

[44]  B. Trask,et al.  The gene for the peripheral myelin protein PMP–22 is a candidate for Charcot–Marie–Tooth disease type 1A , 1992, Nature Genetics.

[45]  P. De Jonghe,et al.  The peripheral myelin protein gene PMP–22 is contained within the Charcot–Marie–Tooth disease type 1A duplication , 1992, Nature Genetics.

[46]  V SCOLPINI,et al.  [Charcot-Marie-Tooth disease]. , 1950, Archivos de pediatria del Uruguay.

[47]  F. Fan,et al.  Abstract: New Engineered Luciferase Reporter from a Deep Sea Shrimp , 2012 .

[48]  K. Nave,et al.  The transcription factor Sox10 is a key regulator of peripheral glial development. , 2001, Genes & development.